CSL Shares Jump 17% After FY26 Reset; Meyka Grades Stock B on August 19

CSL Limited (CSL.AX) surged 17.25% to A$157.82 on Tuesday after reporting its FY2026 results. The biotech giant took a AUD 10 billion write-down tied to its 2022 Vifor acquisition, posting a AUD 3.7 billion statutory loss. Yet investors focused on management’s reset plan: flat FY2027 revenue guidance, 5% underlying earnings growth, and a AUD 1.1 billion share buyback. The stock has fallen 50% over 12 months, making the turnaround signal critical.

Why the write-down and the rally

CSL’s Vifor acquisition has become its biggest liability. Vifor sales grew in FY2026 but are forecast to fall 25% in FY2027 due to generic competition. CSL’s vaccination business Seqirus grew only 2%, below expectations, while its blood plasma division Behring struggled with US oversupply. Underlying revenue and profit both fell slightly in FY2026. Yet the market rewarded the reset: after years of earnings misses and management turnover, CEO Gordon Naylor signaled stabilization and cost discipline. The company delivered USD 176 million in cost savings during the reset year.

The numbers behind the recovery

FY2026 revenue fell 1% to USD 15.8 billion, while underlying NPAT dropped 2% to USD 3.1 billion. For FY2027, management expects underlying NPAT to grow around 5%. The AUD 1.1 billion buyback signals confidence in the turnaround. Investors shrugged off the loss because the reset removes uncertainty and positions the company for sustainable growth ahead.

Meyka data shows mixed signals

Meyka grades CSL a B (Neutral) as of August 18, with a 12-month price forecast of A$78.81. The stock trades at a PE of 16.97 with an RSI of 80.94, signaling overbought conditions after the 17% rally. Debt-to-equity stands at 0.67, and net debt has risen to 1.8 times EBITDA. The company’s ROE of 7.6% and ROA of 3.8% remain weak, though the DCF score of 5 (Strong Buy) suggests undervaluation on fundamentals.

What this means for investors

CSL’s reset removes the overhang of Vifor uncertainty, but execution risk remains high. Vifor’s 25% revenue decline and Seqirus weakness must stabilize for the 5% earnings growth forecast to hold. With the stock up 50% from its 12-month low of A$90, the rally has already priced in much of the turnaround hope. Meyka’s B grade and A$78.81 forecast suggest limited upside from current levels, even as the company’s cost discipline and buyback support the recovery narrative.

Final Thoughts

CSL’s 17% surge reflects relief over the reset, not confidence in immediate growth. The AUD 10 billion write-down clears the Vifor overhang, but Vifor’s 25% revenue decline and weak Seqirus growth remain headwinds. Meyka’s B grade and cautious forecast suggest the market has priced in most of the recovery already.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.